Your browser doesn't support javascript.
loading
Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study.
Rannikko, Antti; Leht, Mare; Mirtti, Tuomas; Kenttämies, Anu; Tolonen, Teemu; Rinta-Kiikka, Irina; Kilpeläinen, Tuomas P; Natunen, Kari; Lilja, Hans; Lehtimäki, Terho; Raitanen, Jani; Kujala, Paula; Ronkainen, Johanna; Matikainen, Mika; Petas, Anssi; Taari, Kimmo; Tammela, Teuvo; Auvinen, Anssi.
Afiliação
  • Rannikko A; Department of Urology, Faculty of Medicine, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
  • Leht M; Research Programme in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Mirtti T; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Kenttämies A; Department of Urology, Hyvinkää Hospital, Helsinki and Uusimaa Hospital District, Hyvinkää, Finland.
  • Tolonen T; Research Programme in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Rinta-Kiikka I; Pathology, HUS Diagnostic Centre, HUS Medical Imaging Centre, Helsinki, Finland.
  • Kilpeläinen TP; Radiology, HUS Diagnostic Centre, HUS Medical Imaging Centre, Helsinki, Finland.
  • Natunen K; Department of Pathology, Fimlab Laboratories, Tampere, Finland.
  • Lilja H; Department of Radiology, Tampere University Hospital, Tampere, Finland.
  • Lehtimäki T; Department of Urology, Faculty of Medicine, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
  • Raitanen J; Research Programme in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Kujala P; Faculty of Social Sciences, Tampere University, Tampere, Finland.
  • Ronkainen J; Departments of Laboratory Medicine, Surgery, and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Matikainen M; Department of Translational Medicine, Lund University, Malmö, Sweden.
  • Petas A; Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland.
  • Taari K; Faculty of Social Sciences, Tampere University, Tampere, Finland.
  • Tammela T; UKK Institute for Health Promotion Research, Tampere, Finland.
  • Auvinen A; Department of Pathology, Fimlab Laboratories, Tampere, Finland.
BJU Int ; 130(2): 193-199, 2022 08.
Article em En | MEDLINE | ID: mdl-34958531
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Antígeno Prostático Específico Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline / Prognostic_studies / Screening_studies Limite: Humans / Male Idioma: En Revista: BJU Int Assunto da revista: UROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Finlândia
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Antígeno Prostático Específico Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline / Prognostic_studies / Screening_studies Limite: Humans / Male Idioma: En Revista: BJU Int Assunto da revista: UROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Finlândia